Jason T Yustein1, Chi V Dang. 1. Division of Pediatric Hematology-Oncology, Johns Hopkins University, Baltimore, Maryland 21205, USA. jyustei1@jhmi.edu
Abstract
PURPOSE OF REVIEW: Burkitt's lymphoma is a unique hematological malignancy remarkable for its biological characteristics, including aberrant expression of the MYC oncogene, and its requirement for intensive treatment regimens. This review will focus on those features, and discuss recent advances in the molecular biology and advancing treatment options for the disease. RECENT FINDINGS: Advances in molecular biology have provided many new insights into the biology and treatment options for Burkitt's lymphoma. Microarray technology has recently been used to define a molecular gene expression signature for Burkitt's lymphoma. This signature allows for the differentiation of Burkitt's lymphoma from other forms of non-Hodgkin's lymphoma such as diffuse large B-cell lymphoma. Recent advances in the use of biological agents, such as rituximab, have also allowed for a reduction in treatment toxicities while still offering comparable survival outcomes for patients. SUMMARY: Burkitt's lymphoma is an interesting mature B-cell non-Hodgkin's lymphoma that has numerous distinct features and clinical variants depending on factors such as geographical location, immunological status and patient's age. Although the role of the MYC oncogene has been well studied, we are only now appreciating the defining molecular characteristics of this disease, and using these advances to improve treatment options for patients.
PURPOSE OF REVIEW: Burkitt's lymphoma is a unique hematological malignancy remarkable for its biological characteristics, including aberrant expression of the MYC oncogene, and its requirement for intensive treatment regimens. This review will focus on those features, and discuss recent advances in the molecular biology and advancing treatment options for the disease. RECENT FINDINGS: Advances in molecular biology have provided many new insights into the biology and treatment options for Burkitt's lymphoma. Microarray technology has recently been used to define a molecular gene expression signature for Burkitt's lymphoma. This signature allows for the differentiation of Burkitt's lymphoma from other forms of non-Hodgkin's lymphoma such as diffuse large B-cell lymphoma. Recent advances in the use of biological agents, such as rituximab, have also allowed for a reduction in treatment toxicities while still offering comparable survival outcomes for patients. SUMMARY:Burkitt's lymphoma is an interesting mature B-cell non-Hodgkin's lymphoma that has numerous distinct features and clinical variants depending on factors such as geographical location, immunological status and patient's age. Although the role of the MYC oncogene has been well studied, we are only now appreciating the defining molecular characteristics of this disease, and using these advances to improve treatment options for patients.
Authors: Jason M God; Dan Zhao; Christine A Cameron; Shereen Amria; Jennifer R Bethard; Azizul Haque Journal: Immunology Date: 2014-07 Impact factor: 7.397
Authors: Yan Xiang; Zachary E Stine; Jinsong Xia; Yunqi Lu; Roddy S O'Connor; Brian J Altman; Annie L Hsieh; Arvin M Gouw; Ajit G Thomas; Ping Gao; Linchong Sun; Libing Song; Benedict Yan; Barbara S Slusher; Jingli Zhuo; London L Ooi; Caroline G L Lee; Anthony Mancuso; Andrew S McCallion; Anne Le; Michael C Milone; Stephen Rayport; Dean W Felsher; Chi V Dang Journal: J Clin Invest Date: 2015-04-27 Impact factor: 14.808
Authors: Ryan M Young; Ian R Hardy; Raedun L Clarke; Nicolai Lundy; Polly Pine; Brian C Turner; Terry A Potter; Yosef Refaeli Journal: Blood Date: 2008-11-03 Impact factor: 22.113
Authors: Roland Schmitz; Ryan M Young; Michele Ceribelli; Sameer Jhavar; Wenming Xiao; Meili Zhang; George Wright; Arthur L Shaffer; Daniel J Hodson; Eric Buras; Xuelu Liu; John Powell; Yandan Yang; Weihong Xu; Hong Zhao; Holger Kohlhammer; Andreas Rosenwald; Philip Kluin; Hans Konrad Müller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Martin D Ogwang; Steven J Reynolds; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Wing C Chan; Stefania Pittaluga; Wyndham Wilson; Thomas A Waldmann; Martin Rowe; Sam M Mbulaiteye; Alan B Rickinson; Louis M Staudt Journal: Nature Date: 2012-08-12 Impact factor: 49.962
Authors: Zhuang Liu; Alice C Fan; Kavya Rakhra; Sarah Sherlock; Andrew Goodwin; Xiaoyuan Chen; Qiwei Yang; Dean W Felsher; Hongjie Dai Journal: Angew Chem Int Ed Engl Date: 2009 Impact factor: 15.336
Authors: Leena V Maramattom; Parameswaran N Hari; Linda J Burns; Jeanette Carreras; William Arcese; Mitchell S Cairo; Luciano J Costa; Timothy S Fenske; Michael Lill; Cesar O Freytes; Robert Peter Gale; Thomas G Gross; Gregory A Hale; Mehdi Hamadani; Leona A Holmberg; Jack W Hsu; David J Inwards; Hillard M Lazarus; David I Marks; David G Maloney; Richard T Maziarz; Silvia Montoto; David A Rizzieri; Baldeep Wirk; James L Gajewski Journal: Biol Blood Marrow Transplant Date: 2012-11-27 Impact factor: 5.742
Authors: Faton T Hoxha; Shemsedin I Hashani; Avdyl S Krasniqi; Fisnik I Kurshumliu; Driton S Komoni; Shpresa M Hasimja; Mehmet Maxhuni Journal: Cases J Date: 2009-12-14